Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.

Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K.

J Biol Chem. 2004 Aug 6;279(32):33456-62. Epub 2004 Jun 3.

2.

Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes.

Obara K, Mizutani M, Hitomi Y, Yajima H, Kondo K.

Clin Nutr. 2009 Jun;28(3):278-84. doi: 10.1016/j.clnu.2009.03.012. Epub 2009 Apr 23.

PMID:
19395131
3.

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML.

J Biol Chem. 2002 Jul 5;277(27):24484-9. Epub 2002 May 6.

4.

Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents.

Yajima H, Noguchi T, Ikeshima E, Shiraki M, Kanaya T, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K.

Int J Obes (Lond). 2005 Aug;29(8):991-7.

PMID:
15852044
5.

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.

PMID:
16199244
6.

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.

Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K.

Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E841-54. Epub 2002 Dec 10.

7.

Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.

Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

Diabet Med. 2010 Feb;27(2):150-6. doi: 10.1111/j.1464-5491.2009.02906.x.

PMID:
20546257
9.

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.

Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9. Epub 2003 Dec 15.

10.

Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.

Clin Endocrinol (Oxf). 2008 Sep;69(3):452-61. doi: 10.1111/j.1365-2265.2008.03231.x. Epub 2008 Mar 10.

PMID:
18331610
11.

KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.

Konda VR, Desai A, Darland G, Grayson N, Bland JS.

PLoS One. 2014 Jan 30;9(1):e87848. doi: 10.1371/journal.pone.0087848. eCollection 2014.

12.

Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.

Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ.

Acta Pharmacol Sin. 2005 May;26(5):575-80.

13.

Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.

Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T.

J Biol Chem. 2006 Mar 31;281(13):8748-55. Epub 2006 Jan 23.

15.

Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.

Laurent D, Gounarides JS, Gao J, Boettcher BR.

Diabetes Obes Metab. 2009 Jun;11(6):632-6. doi: 10.1111/j.1463-1326.2008.01017.x. Epub 2009 Jan 19.

PMID:
19175377
16.

Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.

Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K.

Cancer Res. 2003 Sep 15;63(18):6090-5.

17.

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML.

J Biol Chem. 2003 Sep 5;278(36):34268-76. Epub 2003 Jun 11.

18.

Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.

Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B.

J Biol Chem. 2001 Feb 16;276(7):4634-9. Epub 2000 Oct 24.

19.

Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.

Mustad VA, Demichele S, Huang YS, Mika A, Lubbers N, Berthiaume N, Polakowski J, Zinker B.

Metabolism. 2006 Oct;55(10):1365-74.

PMID:
16979408
20.

Supplemental Content

Support Center